Does Insulin Cause Weight Gain?

Many people with diabetes need to use insulin to manage their blood sugar. But this vital medication often has a frustrating side effect: weight gain.
When people with type 1 or type 2 diabetes are prescribed insulin, it’s common for them to put on some extra pounds, says Tom Wadsworth, PharmD, the dean and an associate professor at L.S. Skaggs College of Pharmacy at Idaho State University in Pocatello. “However,” Dr. Wadsworth says, “it’s not inevitable, and some patients successfully prevent or even lose weight with the right strategies.”
Is There an Ideal Type 2 Diabetes Diet?

Next up video playing in 10 seconds
Insulin and Weight Gain
One of the other primary functions of insulin is to facilitate fat storage, which is where weight gain can come into play.
“Insulin's job is to help store energy, so when someone eats more calories than they burn — especially in response to low blood sugar or increased appetite — the body is more likely to store fat instead of burning it,” says Wadsworth.
“Insulin can stimulate appetite, especially when blood sugar levels drop,” he says. “Some people also experience increased cravings for sweet or high-calorie foods, as insulin plays a role in reward and taste perception in the brain.”
The type of insulin you take may be more likely to cause weight gain than other types.
“The rapid, short, and intermediate acting insulins have been associated with the most weight gain, while longer-acting formulations tend to cause less weight gain — though they can still contribute to it,” says Ravi Retnakaran, MD, a professor of medicine at the University of Toronto.
Type 1 Diabetes and Insulin Weight Issues
“Some people are understandably fearful of hypoglycemia and its implications, so they try to keep their blood sugars elevated by eating, and doing so, you’re getting excessive calories that can contribute to weight gain,” says Dr. Retnakaran.
Type 2 Diabetes and Insulin Weight Gain
“Weight gain is largely driven by calorie intake and metabolic shifts. Careful insulin dose adjustments, meal planning, and regular activity can minimize or even prevent weight gain,” says Wadsworth.
Diabetes Medication Options That Spark Weight Loss
In recent years, two newer families of type 2 diabetes drugs have made it easier to find glucose-lowering treatments that spur weight loss instead of weight gain.
- GLP-1 and dual GIP/GLP-1 receptor agonists, including semaglutide (Ozempic) and tirzepatide (Mounjaro), have a potent glucose-lowering effect and are proving to be very effective weight loss drugs for many who take them. “They have been game changers in the management of type 2 diabetes,” says Wadsworth. GLP-1s promote weight loss by reducing appetite and keeping your stomach full longer, among other factors. “Type 2 patients can lose up to 25 percent of their body weight within a year, which greatly reduces their insulin-resistance, precluding the need for insulin therapy.”
- SGLT2 inhibitors, including empagliflozin (Jardiance) and dapagliflozin (Farxiga), lower blood sugar levels and protect kidney and heart health while inducing modest weight loss. “SGLT2 inhibitors can lead to weight loss or stabilization, but not as much as the GLP-1 agonists,” says Retnakaran.
“Both drug classes have become preferred options for managing type 2 diabetes, especially in obese patients or those at risk of weight gain, particularly when insulin therapy is required,” says Wadsworth. “More importantly, these medications offer significant cardiovascular and kidney benefits, reducing the risk of heart attacks and other serious diabetes-related complications — benefits that insulin therapy does not provide.”
Preventing Excess Weight Gain on Insulin Therapy
It’s dangerous to reduce or adjust insulin dosing without consulting a doctor first. Talk to your medical team about the interactions between your insulin dosage and your diet, exercise habits, and other medications. Weight gain is not inevitable. “Balancing insulin dosing and meal timing can help reduce that effect,” says Wadsworth. Here are other healthy lifestyle tips to help you keep the scale at the weight you want.
Eat Healthier
“I always have my patients see a dietitian, so they are following healthy dietary patterns,” says Retnakaran. “A dietitian can work with you to optimize your eating in the context of your preferences and give you healthy suggestions.”
Sometimes, when we feel hungry, we may just be thirsty. Choose water, and you’ll take an essential step toward being hydrated and feeling fuller. It’s a healthy beverage that won’t spike your blood glucose levels like sugary sodas or sweetened fruit juice.
Exercise Regularly
Ask About Adjusting Your Medications
If you have type 2 diabetes, ask your healthcare provider about potentially switching to GLP-1 or SGLT2 drugs, which can cause weight loss — instead of weight gain — and lower your blood glucose levels.
“These drugs can help offset the weight gain caused by insulin, and in most cases of type 2 diabetes, can be used to help patients avoid insulin therapy altogether," says Wadsworth.
The Takeaway
- Insulin therapy is essential for many people who have diabetes, but it often leads to weight gain due to the hormone’s role in fat storage.
- Weight gain is not inevitable if you take insulin. A healthy diet and a commitment to regular exercise can improve your insulin sensitivity and reduce your need for extra insulin, potentially slowing, preventing, or reversing weight gain.
- Other type 2 diabetes medicines that have a weight loss effect, like GLP-1 receptor agonists and SGLT2 inhibitors, may be alternatives or additions to insulin therapy that can counteract weight gain.
Resources We Trust
- Mayo Clinic: Insulin and Weight Gain: Keep the Pounds Off
- Cleveland Clinic: Natural Appetite Suppressants: Tips to Feel Fuller, Longer
- The DiaTribe Foundation: 6 Benefits of Combining Insulin and GLP-1 Drugs
- National Health Service: Insulin for Type 2 Diabetes
- American Diabetes Association: Exercising With Diabetes Complications
Additional reporting by Jessica Freeborn.
- Insulin. Cleveland Clinic. January 17, 2024.
- Nathan DM. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview. Diabetes Care. December 11, 2013.
- Röhling M et al. Weight Reduction by the Low-Insulin-Method — a Randomized Controlled Trial. Nutrients. September 30, 2020.
- Van der Schueren B et al. Obesity in People Living With Type 1 Diabetes. Lancet. November 2021.
- Mottalib A et al. Weight Management in Patients with Type 1 Diabetes and Obesity. Current Diabetes Reports. August 23, 2017.
- Understanding Fear of Hypoglycemia in People With Diabetes. National Institute of Diabetes and Digestive and Kidney Diseases. January 15, 2025.
- Coleman SE et al. Diabetes and Eating Disorders: An Exploration of “Diabulimia”. BMC Psychology. September 23, 2020.
- Wesling M et al. Diabetes: How to Manage Overweight and Obesity in Type 2 Diabetes Mellitus. Drugs in Context. June 14, 2022.
- Chandrasekaran P et al. The Role of Obesity in Type 2 Diabetes Mellitus — an Overview. International Journal of Molecular Sciences. February 4, 2024.
- Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes–2025. Diabetes Care. December 2024.
- Understanding New Weight-Loss Drugs. Harvard Health Publishing. November 1, 2023.
- Danpanichkul P et al. Predictors of weight reduction effectiveness of SGLT2 Inhibitors in Diabetes Mellitus Type 2 Patients. Frontiers in Endocrinology. January 23, 2024.
- Carris NW et al. Combining a GLP-1 Receptor Agonist and Basal Insulin: Study Evidence and Practical Considerations. Drugs. December 2014.
- Harris SB et al. When Insulin Therapy Fails: The Impact of SGLT2 Inhibitors in Patients with Type 2 Diabetes. Diabetes Care.
- Edwards K et al. Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study. Journal of Clinical Endocrinology & Metabolism. October 21, 2022.
- Reynolds A et al. Dietary Advice For Individuals with Diabetes. Endotext. April 28, 2024.
- Weekly Exercise Targets. American Diabetes Association.

Anna L. Goldman, MD
Medical Reviewer
Anna L. Goldman, MD, is a board-certified endocrinologist. She teaches first year medical students at Harvard Medical School and practices general endocrinology in Boston.
Dr. Goldman attended college at Wesleyan University and then completed her residency at Icahn School of Medicine at Mount Sinai Hospital in New York City, where she was also a chief resident. She moved to Boston to do her fellowship in endocrinology at Brigham and Women's Hospital. She joined the faculty after graduation and served as the associate program director for the fellowship program for a number of years.

Maria Muccioli, PhD
Author
Maria Muccioli, PhD, is the director of research at Thrivable, a healthcare market research firm specializing in patient experiences. Diagnosed with type 1 diabetes during her undergraduate studies in biochemistry, she was inspired to pursue a career in immunology.
She earned her PhD in molecular and cellular biology from Ohio University and completed postdoctoral research at The Ohio State University, as well as a fellowship at Brigham and Women's Hospital and Harvard Medical School. Throughout her postdoctoral tenure, Maria contributed to significant research across various health conditions, including diabetes, cancer, and multiple sclerosis.
Her work has been recognized by the Greenbook Future List, which honored her as a 2024 recipient for her contributions to the insights industry. Maria is passionate about delivering up-to-date, evidence-based information to the diabetes community and has authored over 100 articles on living with diabetes. She firmly believes in empowering individuals with diabetes to manage their condition effectively and enjoys connecting with the community through her writing and on social media.
Maria currently resides in Florida with her husband, two children, and a variety of pets.